Neurolixis Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research

--NLX-112 to Undergo PK/PD Study Prior to Clinical Trial Targeting Levodopa-induced Dyskinesia--

Dana Point, CA. 8 August, 2014 -- Neurolixis Inc. today announced that it had been awarded a research grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to carry out a detailed pharmacokinetic / pharmacodynamic (PK/PD) analysis of its lead clinical candidate, NLX-112.

NLX-112, an exceptionally selective and efficacious serotonin 5-HT1A receptor agonist, is being developed by Neurolixis for the treatment of levodopa-induced dyskinesia (LID). Dyskinesias are uncontrollable and disruptive movements caused by long-term use of anti-parkinsonian drugs such as levodopa. There is no FDA-approved treatment for dyskinesia, and it remains a significant unmet medical need because of its negative impact on patients' quality of life.

In previous studies funded by the MJFF, NLX-112 was tested in a rat model of Parkinson's disease where it very potently and completely reversed L-DOPA-induced dyskinesia. This effect was maintained upon chronic administration and was associated with sustained effects on neurotransmitter levels in the striatum, an important brain region involved in motor control.

With the latest grant, Neurolixis will carry out a PK/PD modeling study of NLX-112 to assist in dosing predictions prior to a proof-of-concept clinical trial of NLX-112 in PD patients suffering from troubling LID. Specifically, the project will investigate the blood plasma and brain tissue pharmacokinetics of NLX-112. In addition, the study will investigate the transport of NLX-112 by blood-brain barrier transporters and the brain 5-HT1A receptor occupancy by brain imaging. The data generated from these studies will be analyzed using computer modeling to generate predictions of optimal dose ranges for design of a Phase II clinical trial. NLX-112 has been previously tested in several hundred subjects for another indication before being re-purposed by Neurolixis as a treatment for LID.

"We are delighted with the very robust anti-dyskinetic profile of NLX-112 in preclinical tests. The data generated thus far are highly compelling and suggest that NLX-112 could constitute an effective therapy for PD patients suffering from levodopa-induced dyskinesia", commented Dr. Adrian Newman-Tancredi, Principal Investigator on the project and Chief Scientific Officer of Neurolixis.

About Dyskinesia in Parkinson's disease

A lack of the neurotransmitter dopamine underlies motor symptoms in PD, and dopamine replacement with its precursor, levodopa, is a mainstay of anti-parkinsonian therapy. However, upon long-term administration, levodopa elicits motor complications characterized by involuntary movements called dyskinesia. Chorea is the most common form of dyskinesia and refers to involuntary, rapid, irregular and purposeless movements. Dyskinesia may predominantly affect particular body parts — for example, torso, head and neck, limbs — or speech or respiratory muscles. Dystonia is the second most common form of levodopa-induced dyskinesia, presenting as sustained muscle contractions. It can occur either alone or in combination with chorea, in the latter case manifesting as twisting of the leg when walking, or the arm being pulled behind the back. Most PD patients treated with levodopa will eventually develop dyskinesia.

About The Michael J. Fox Foundation for Parkinson's Research

As the world's largest non-profit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $450 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us on Facebook, Twitter, Web and LinkedIn.

About Neurolixis, Inc.

Neurolixis, located in southern California, is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of psychiatric disorders such as depression and schizophrenia, and neurological disorders such as Parkinson's disease and Rett syndrome. Additional information regarding Neurolixis is available at http://www.neurolixis.com.

PRESS CONTACTS

Dr Mark Varney, CEO Neurolixis,
mvarney@neurolixis.com
(949) 214-4017

Forward Looking Statement

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.